To date, several selective FGFR inhibitors have been tested in clinical trials in patients with ER+ breast cancer harboring FGFR1 amplification, but sensitivity to FGFR inhibitors has not been determined by FGFR1 amplification [31,32]. The gene discussed is FGFR1; the disease is breast carcinoma.